Last reviewed · How we verify
bupivacain 0.5%
At a glance
| Generic name | bupivacain 0.5% |
|---|---|
| Also known as | marcaine, Pure Bupivacain 0.5% |
| Sponsor | The Baruch Padeh Medical Center, Poriya |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Sidekick vs Conventional Cannula in Lumbar Medial Branch Radiofrequency Ablation (NA)
- Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind Trial (NA)
- Dexmedetomidine as an Adjuvant to Bupivacaine in Bilateral PECs for Pain Control After Cardiac Surgeries (PHASE4)
- Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord Stimulation to Intrathecal Drug Delivery. (PHASE4)
- Compared With Different Method for Postcesarean Section Analgesia (NA)
- Spinal Analgesia in Labour Pain (PHASE1)
- Superficial Cervical Plexus Block With Dexmedetomidine Versus Without Adjuvant in Thyroid Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupivacain 0.5% CI brief — competitive landscape report
- bupivacain 0.5% updates RSS · CI watch RSS
- The Baruch Padeh Medical Center, Poriya portfolio CI